anti-BRAF (BRAF) Antikörper

Bezeichnung:
anti-V-Raf Murine Sarcoma Viral Oncogene Homolog B1 Antikörper (BRAF)
Auf www.antikoerper-online.de finden Sie aktuell 405 V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) Antikörper von 24 unterschiedlichen Herstellern. Zusätzlich bieten wir Ihnen BRAF Proteine (34) und BRAF Kits (7) und viele weitere Produktgruppen zu diesem Protein an. Insgesamt sind aktuell 468 BRAF Produkte verfügbar.
Synonyme:
9930012E13Rik, AA120551, AA387315, AA473386, B-raf, B-RAF1, Braf, Braf-2, BRAF1, Braf2, C-RMIL, C87398, C230098H17, D6Ertd631e, HYPT11, NS7, RAFB1, RMIL, sierrabraf, Sm-E, SME

Meistgesuchte Reaktivitäten zu anti-BRAF (BRAF) Antikörper

Wählen Sie die Spezies und Applikation aus

anti-Mouse (Murine) BRAF Antikörper:

anti-Human BRAF Antikörper:

anti-Rat (Rattus) BRAF Antikörper:

Alle verfügbaren anti-BRAF Antikörper

Sie gelangen zu unserer vorgefilterten Suche.

Am meisten referenzierte anti-BRAF Antikörper

  1. Human Polyclonal BRAF Primary Antibody für EIA - ABIN358444 : Loewe, Kittler, Fischer, Faé, Wolff, Petzelbauer: BRAF kinase gene V599E mutation in growing melanocytic lesions. in The Journal of investigative dermatology 2004 (PubMed)
    Zeige alle 5 Referenzen für 358444

  2. Human Polyclonal BRAF Primary Antibody für EIA - ABIN358356 : Yamaguchi, Wallace, Magenheimer, Hempson, Grantham, Calvet: Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. in The Journal of biological chemistry 2004 (PubMed)
    Zeige alle 5 Referenzen für 358356

  3. Human Polyclonal BRAF Primary Antibody für EIA - ABIN358271 : Tsavachidou, Coleman, Athanasiadis, Li, Licht, Olson, Weber: SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. in Cancer research 2004 (PubMed)
    Zeige alle 5 Referenzen für 358271

  4. Human Polyclonal BRAF Primary Antibody für EIA - ABIN358344 : Frattini, Ferrario, Bressan, Balestra, De Cecco, Mondellini, Bongarzone, Collini, Gariboldi, Pilotti, Pierotti, Greco: Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. in Oncogene 2004 (PubMed)
    Zeige alle 5 Referenzen für 358344

  5. Human Polyclonal BRAF Primary Antibody für EIA, IHC (p) - ABIN360131 : Hingorani, Jacobetz, Robertson, Herlyn, Tuveson: Suppression of BRAF(V599E) in human melanoma abrogates transformation. in Cancer research 2003 (PubMed)
    Zeige alle 3 Referenzen für 360131

  6. Human Polyclonal BRAF Primary Antibody für EIA, IHC (p) - ABIN360136 : Lee, Yoo, Soung, Kim, Park, Kim, Lee, Park, Cho, Kim, Ko, Kim, Nam, Lee, Lee: BRAF mutations in non-Hodgkin's lymphoma. in British journal of cancer 2003 (PubMed)
    Zeige alle 3 Referenzen für 360136

  7. Human Polyclonal BRAF Primary Antibody für EIA, IHC (p) - ABIN360132 : Davies, Bignell, Cox, Stephens, Edkins, Clegg, Teague, Woffendin, Garnett, Bottomley, Davis, Dicks, Ewing, Floyd, Gray, Hall, Hawes, Hughes, Kosmidou, Menzies, Mould, Parker, Stevens, Watt, Hooper et al.: Mutations of the BRAF gene in human cancer. ... in Nature 2002 (PubMed)
    Zeige alle 3 Referenzen für 360132

  8. Human Polyclonal BRAF Primary Antibody für DB - ABIN389897 : Duan, Cobb: Calcineurin increases glucose activation of ERK1/2 by reversing negative feedback. in Proceedings of the National Academy of Sciences of the United States of America 2010 (PubMed)
    Zeige alle 3 Referenzen für 389897

  9. Human Polyclonal BRAF Primary Antibody für IHC (p), WB - ABIN392248 : Naoki, Chen, Richards, Sugarbaker, Meyerson: Missense mutations of the BRAF gene in human lung adenocarcinoma. in Cancer research 2002 (PubMed)
    Zeige alle 3 Referenzen für 392248

Weitere Antikörper gegen BRAF Interaktionspartner

Xenopus laevis V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) Interaktionspartner

  1. BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Xenopus, but exon 8b is present only in eutherians.

Zebrafish V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) Interaktionspartner

  1. Gene expression studies nominated TWIST2 (zeige TWIST2 Antikörper) as a key effector downstream of BRAF.

  2. BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Danio rerio, but exon 8b is present only in eutherians.

  3. BRAF activation is sufficient for f-nevus formation, and is among the primary events in melanoma development.

Chimpanzee V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) Interaktionspartner

  1. BRAF alternative splicing is differentially regulated in rodent and primates. Exon 9b is present in vertebrates but exon 8b is present only in eutherians.

Mouse (Murine) V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) Interaktionspartner

  1. This study detected the BrafV637E mutation by whole-exome analysis in 4/4 hepatic tumors induced by neonatal treatment with diethylnitrosamine (DEN) in male B6C3F1 mice.

  2. a critical threshold for inhibition of MAPK (zeige MAPK1 Antikörper) signaling is required to optimally restore expression of thyroid differentiation genes in thyroid cells and in mice with BrafV600E-induced thyroid cancer.

  3. A- and B-Raf ablation in chondrocytes does not alter skeletal development, whereas ablation of C-Raf decreases hypertrophic chondrocyte apoptosis and impairs vascularization of the growth plate. However, ablation of C-Raf does not impair phosphate-induced ERK1/2 phosphorylation in vitro, but leads to rickets by decreasing VEGF protein stability.

  4. these contrasting signatures precisely match those proposed to confer bias toward Hras (zeige HRAS Antikörper)(CAA61CTA) versus Braf(GTG636GAG) mutations in the original tumor sets. Our findings highlight a novel mechanism whereby exposure history acts through strand-biased mutagenesis to specify activation of preferred oncogenes

  5. these results suggest that the activation of 5-HT1D receptors selectively enhanced IA via the Gbetagamma of the Go-protein, PKA, and the sequential B-Raf (zeige SNRPE Antikörper)-dependent p38 MAPK (zeige MAPK14 Antikörper) signaling cascade.

  6. BRAF V600E inhibition stimulates AMP-activated protein kinase (zeige PRKAA2 Antikörper)-mediated autophagy in colorectal cancer cells.

  7. these data confirm the existence of a negative feedback pathway by which BRAF protein stability is regulated by ERK (zeige EPHB2 Antikörper).

  8. coexpression of BRAF(V600E) and KRAS(G12D) in early tumorigenesis leads to negative selection due to oncogene (zeige RAB1A Antikörper)-induced senescence

  9. findings suggest that targeting ErbB-3 (zeige ERBB3 Antikörper) receptors could represent an effective therapeutic approach in BRAF-V600E mutant colon cancer

  10. Atg7 (zeige ATG7 Antikörper) Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma

Human V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) Interaktionspartner

  1. Increased plasma membrane abundance of PMCA4b (zeige ATP2B4 Antikörper) in vemurafenib-treated BRAF mutant cells is associated with enhanced Ca2 (zeige CA2 Antikörper)+ clearance.

  2. Data indicate the role of immunohistochemical BRAF V600E expression in patients at the time of progression.

  3. BRAF, FGFR1 (zeige FGFR1 Antikörper), and MYB (zeige MYB Antikörper) mutations occur at high frequency and align with morphology of low-grade neuroepithelial tumors

  4. In this report, we describe a 35-year-old female who presented with multifocal ganglioglioma, involving both the conus medullaris and filum terminale. The dominant lesion in the filum terminale was resected, which revealed World Health Organization I grade, p53 (zeige TP53 Antikörper) mutant, and BRAF wildtype status

  5. Studies indicate the clinical importance of BRAF-V600 mutations and BRAF inhibition in the progression to melanoma brain metastasis.

  6. IRP2 (zeige IREB2 Antikörper) expression was associated with mutations in BRAF.

  7. BRAF mutations were present in 44.6% of primary papillary thyroid carcinomas, 41.7% of lymph node metastasis, and 23.8% of distant metastasis.

  8. Mutation in BRAF gene is associated with Pancreatic Ductal Adenocarcinoma.

  9. Patients with BRAF V600E PLGG exhibited poor outcomes after chemotherapy and radiation therapies that resulted in a 10-year progression-free survival of 27% (95% CI, 12.1% to 41.9%) and 60.2% (95% CI, 53.3% to 67.1%) for BRAF V600E and wild-type PLGG, respectively ( P < .001).

  10. RNF43 (zeige RNF43 Antikörper) germline and somatic mutation in Serrated Neoplasia pathway associated with BRAF mutation.

Horse (Equine) V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) Interaktionspartner

  1. BRAF alternative splicing is differentially regulated in rodent and primates. Exon 9b is present in vertebrates but exon 8b is present only in eutherians.

BRAF Antigen-Profil

Beschreibung des Gens

This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene.

Alternative names and synonyms associated with BRAF

  • v-raf murine sarcoma viral oncogene homolog B (braf) Antikörper
  • v-raf murine sarcoma viral oncogene homolog B1 (braf) Antikörper
  • v-raf murine sarcoma viral oncogene homolog B1 (BRAF) Antikörper
  • v-raf murine sarcoma viral oncogene homolog B1 (LOC100219601) Antikörper
  • Braf transforming gene (Braf) Antikörper
  • Braf transforming gene, related sequence 1 (Braf-rs1) Antikörper
  • small nuclear ribonucleoprotein polypeptide E (SNRPE) Antikörper
  • v-raf murine sarcoma viral oncogene homolog B (BRAF) Antikörper
  • v-raf murine sarcoma viral oncogene homolog B (Braf) Antikörper
  • 9930012E13Rik Antikörper
  • AA120551 Antikörper
  • AA387315 Antikörper
  • AA473386 Antikörper
  • B-raf Antikörper
  • B-RAF1 Antikörper
  • Braf Antikörper
  • Braf-2 Antikörper
  • BRAF1 Antikörper
  • Braf2 Antikörper
  • C-RMIL Antikörper
  • C87398 Antikörper
  • C230098H17 Antikörper
  • D6Ertd631e Antikörper
  • HYPT11 Antikörper
  • NS7 Antikörper
  • RAFB1 Antikörper
  • RMIL Antikörper
  • sierrabraf Antikörper
  • Sm-E Antikörper
  • SME Antikörper

Bezeichner auf Proteinebene für BRAF

B-Raf , serine/threonine protein kinase BRAF , v-raf murine sarcoma viral oncogene homolog B1 , serine/threonine-protein kinase B-raf , serine/threonine-protein kinase B-raf-like , B-Raf proto-oncogene serine/threonine-protein kinase (p94) , proto-oncogene B-Raf , sm protein E , small nuclear ribonucleoprotein E , snRNP-E , 94 kDa B-raf protein , murine sarcoma viral (v-raf) oncogene homolog B1 , B-raf protein , B-Raf proto-oncogene serine/threonine-protein kinase , proto-oncogene c-Rmil , rmil serine/threonine-protein kinase , serine/threonine kinase , serine/threonine-protein kinase Rmil

GENE ID SPEZIES
398973 Xenopus laevis
403065 Danio rerio
463781 Pan troglodytes
100219601 Taeniopygia guttata
100442288 Pongo abelii
109880 Mus musculus
110709 Mus musculus
6635 Homo sapiens
673 Homo sapiens
114486 Rattus norvegicus
536051 Bos taurus
475526 Canis lupus familiaris
396239 Gallus gallus
100065760 Equus caballus
Ausgewählte Anbieter für anti-BRAF (BRAF) Antikörper
Haben Sie etwas anderes gesucht?